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Abstract
Aryl hydrocarbon receptor (AhR) is a biological sensor that integrates environ-
mental, metabolic, and endogenous signals to control complex cellular responses in 
physiological and pathophysiological functions. The full-length AhR encompasses var-
ious domains, including a bHLH, a PAS A, a PAS B, and transactivation domains. With 
the exception of the PAS B and transactivation domains, the available 3D structures of 
AhR revealed structural details of its subdomains interactions as well as its interaction 
with other protein partners. Towards screening for novel AhR modulators homol-
ogy modeling was employed to develop AhR-PAS B domain models. These models 
were validated using molecular dynamics simulations and binding site identification 
methods. Furthermore, docking of well-known AhR ligands assisted in confirming 
these binding pockets and discovering critical residues to host these ligands. In this 
context, virtual screening utilizing both ligand-based and structure-based methods 
screened large databases of small molecules to identify novel AhR agonists or antago-
nists and suggest hits from these screens for validation in an experimental biological 
test. Recently, machine-learning algorithms are being explored as a tool to enhance 
the screening process of AhR modulators and to minimize the errors associated with 
structure-based methods. This chapter reviews all in silico screening that were focused 
on identifying AhR modulators and discusses future perspectives towards this goal.
Keywords: human AhR, in silico, in vitro, AhR modulator, crystal structure,  
AhR modeling
1. Introduction
Six decades ago, researchers made extensive studies to answer a puzzling 
question. That was how administrating exogenous substances such as polycyclic 
aromatic hydrocarbons (PAHs) had a potent induction on xenobiotic-metabolizing 
enzymes in rats’ livers [1, 2]. It was finally Alan Poland and his colleagues who 
finally answered this question in the early 1970s. Poland discovered a novel 
hepatic protein in complex with the polycyclic aromatic hydrocarbons compound, 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [2]. The new protein was bound to 
TCDD in a potent affinity and was isolated from hepatic cytosolic fractions of mice 
C57BL/6, a mice model strain for studying aromatic hydrocarbon responsiveness. 
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This protein was later termed as the aryl hydrocarbon receptor (AhR) [2] and was 
identified as a ligand-activated transcription factor.
Later studies showed that AhR is expressed in several tissues including but 
not limited to; liver, lung, placenta, and heart and different cell types throughout 
the developmental periods of organ growth [3]. Further knockout studies in mice 
revealed essential functions for AhR in multiple physiological and pathophysiologi-
cal pathways [4–6]. This accumulated knowledge over the last decades defined AhR 
as an environmental sensor for air pollutants and as a ligand-activated transcrip-
tional factor, which regulates the expression of various genes, including enzymes 
responsible for xenobiotic metabolism [7].
AhR-mediates the toxicity of uncountable xenobiotics, and their triggered 
toxicity is accompanied by an overexpression and overactivation of AhR in cells. 
Thus, it increases the pathophysiological functions of AhR and could develop 
cancer in different organs such as the breast and liver. In addition, it can also lead 
to cardiovascular diseases, among other diseases [8, 9]. Thus, targeting AhR with a 
small molecule agonist/antagonist could efficiently inhibit several of the important 
hallmarks of various cancers [10].
Computational modeling and computer simulations continue to be an important 
tool for studying various biological mechanisms and for analyzing the interactions 
between biomolecular entities (e.g. proteins, DNA, and drugs). These methods use 
complex physiochemical and mathematical algorithms to predict the interactions 
between ligands and proteins at the atomistic level [11]. For instance, in the case of 
AhR, several computational studies have been reported to screen the chemical space 
for potential AhR modulators and to investigate how these ligands interact with 
the individual residues within AhR [12, 13]. This chapter will focus on summariz-
ing the findings and computational approaches described in these studies. The 
chapter first discusses current knowledge related to AhR functions and describes all 
reported AhR crystal structures. It will then provide an overview on the different 
computational studies reported in the literature, which focused on investigating 
AhR dynamics and on identifying novel AhR modulators. We hope the information 
provided in this chapter can advance the development of AhR ligands and contrib-
ute to progress in this important research area.
2. AhR structure and functions
2.1 AhR domain structure
AhR is a member of the basic helix–loop–helix (bHLH)-PER- ARNT-SIM 
(PAS) family of transcription factors. The “PAS” term is an abbreviation for three 
proteins, namely, the Drosophila circadian rhythm protein period (Per), the 
mammalian AhR nuclear translocator (ARNT), and Drosophila neurogenic protein 
single-minded (Sim) [7, 14, 15]. Human AhR is a 848 amino acid with a molecular 
weight of ~96 kDa [16]. It includes two PAS domains, namely PAS A and PAS B, and 
interacts with the Aryl hydrocarbon nuclear tranlocator (ARNT) protein. Moreover, 
the PAS B domain involves two interactions sites: a ligand-binding site in which a 
bound ligand can modulate the AhR activity; and a direct binding interface for the 
HSP 90-chaperone protein. Additionally, AhR includes a basic helix loop helix motif 
located near its N-terminal domain, which is responsible for DNA binding as well as 
contributing to other protein–protein interactions. Finally, the transactivation (i.e., 
glutamine-rich region) domain is located close to the C-terminal of AhR and binds 
to a co-activator [7] as shown in Figure 1.
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2.2 The AhR ligands and their modes of action
The AhR PAS B domain can interact with both exogenous and endogenous 
chemicals from various origins. These interactions can induce different effects on 
AhR activity, leading to a wide range of physiological and toxicological downstream 
consequences. For example, several studies showed that environmental pollutants 
have been associated with developing cardiovascular diseases, cancer, and other 
diseases through AhR modulation [7, 17, 18]. Exogenous AhR ligands include vari-
ous aromatic hydrocarbon molecules such as dioxins. One can be exposed to such 
ligands through contaminated food or environmental pollutants. Following expo-
sure, their interaction with AhR can lead to several toxic effects, including organ 
dysfunctions, immunotoxicity, and carcinogenicity. On the other hand, endogenous 
AhR ligands are usually metabolic derivatives derived from cellular processes such 
as 6-Formylindolo (3,2- b) carbazole (FICZ). The interaction of these ligands with 
AhR is part of a normal functional response through AhR modulation [7, 19, 20].
2.3 AhR physiological and pathophysiological roles
AhR is an essential protein that contributes to countless biological pathways 
to establish its physiological role in developing the immune system and regulat-
ing xenobiotic enzymes [7, 15, 21]. AhR knockout mice models showed abnormal 
female reproductive functions and impairment in managing blood pressure [7]. 
The overactivation and constitutive activation of AhR have been associated with 
the initiation, promotion, progression, and invasion of cancer cells. For example, 
activating AhR by exogenous AhR ligands can have several effects, which includes 
inducing cell proliferation in the G1-S phase, silencing tumor suppressor genes, and 
activating proto-oncogenes in cancer cell lines.
Earlier findings showed that the exogenous AhR ligand, 2,3,7,8-tetrachlorod-
ibenzo-p-dioxin TCDD promoted the degradation of cell–cell adhesion and expan-
sion of cancer cells’ motility by separating the Src kinase from the AhR protein 
complex. Furthermore, the activation of AhR via environmental pollutants can lead 
to a significant induction of xenobiotic-metabolizing enzymes, including CYP1A, 
which produces reactive intermediate metabolites and reactive oxygen species to 
promote tumor growth [14, 22]. In a nutshell, AhR resembles a machinery of genes, 
which controls xenobiotic-metabolizing enzymes in phases I and II, as shown in 
Table 1. Also, known AhR agonists such as TCDD and β -naphthoflavone have been 
shown to induce cellular hypertrophic actions on H9c2 cardiomyoblast cells. This 
was correlated with an increase in the levels of numerous cytochrome P450 genes, 
which could overcome by using an AhR antagonist [23].
On the positive side, experiments on a mouse model of induced colitis showed 
that the endogenous AhR agonist (FICZ), which has a strong binding affin-
ity towards AhR, could block IL-6 and claudin-2 expression, and prevent any 
induced disorders in the intestinal barrier function through AhR activation [24]. 
Figure 1. 
AhR domain structure and sub-domains’ functions.
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Further protein knockout studies showed that AhR ligands play a fundamental 
role in autoimmune diseases through regulating Tregs and TH17 cell differentia-
tion in the immune system. For example, FICZ inhibited Treg and TH17 cell 
development, accelerating experimental autoimmune encephalomyelitis in mice 
models [21, 25].
2.4 AhR signaling pathways
AhR is generally expressed in its inactive form in the cytoplasm as part of a pro-
tein complex encompassing a dimer heat shock protein, co-chaperone p23, an AhR-
interacting protein, called AIP, and the protein kinase SRC (see Figure 2). The PAS 
Figure 2. 
Canonical pathway of aryl hydrocarbon receptor.
Metabolism phase Gene Reference
Phase I CYP1A1 [26]
Phase I CYP1A2 [27]
Phase I CYP1B1 [28]
Phase I CYP2S1 [29]
Phase II NQO1 NAD(P)H: Quinine oxidoreductase 1 [30]
Phase II GSTA1 Glutathione transferase A1/2 [31]
Phase II UGT1A6 Uridine diphosphate glucuronosyltransferase 1A6 [32]
Phase II ALDH3A1 Aldehyde dehydrogenase 3A1 [33]
Table 1. 
Xenobiotic metabolizing enzymes genes regulate via AhR pathway.
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B domain within AhR binds to one monomer of the HSP90 dimer and the second 
HSP90 monomer interacts with the AhR basic helix–loop–helix domain (bHLH) 
as well as with the PAS A domain [34]. As shown in Figure 2, the bHLH domain 
within AhR is also crucial for DNA binding in a process initiated by the binding of 
an AhR ligand within the PAS B domain and its interaction with the co-chaperone 
P23. Binding to P23 stabilizes AhR in the cytoplasm, protecting it from proteasomal 
degrading, and also maintains the PAS B domain of AhR in a unique conformation, 
suitable for strong ligand binding [35, 36].
Once an AhR ligand binds to the PAS B domain, it forms an AhR-ligand com-
plex, including p23, SRC, and AIP (see Figure 2). This complex is transformed into 
an active state and then translocated inside the nucleus. Then in the nucleus, all 
complex components dissociate from the AhR-ligand complex, excluding an agonist 
and AhR protein. Subsequently, AhR forms an active heterodimer with ARNT and 
creates an AhR–ARNT complex. This complex is then recruited to the DNA via the 
Dioxin response element (DRE), exhibiting a common DNA compromise motif 
(5′-TNGCGTG-3). This canonical AhR pathway increases the expression of vari-
ous genes, including the principal ones in xenobiotic metabolism, AhR repressor 
(AHRR), and other genes [36].
3. AhR three-dimensional structures
Resolving the full-length three-dimensional structure of AhR has been a chal-
lenging exercise for the last two decades. Unfortunately, despite the many efforts 
towards this goal, there is no complete structure for the whole AhR protein. 
However, as discussed below, there are a few structures, which describe the number 
AhR domains. Although these structures do not reveal the exact overall AhR archi-
tecture, they can still provide useful information on the function of these separate 
domains. Giving computational modeling a favorable vantage point to construct 
reliable hypotheses for the full-length AhR organization for rational drug develop-
ment and drug screening campaigns.
The first AHR 3D structure was reported in 2013 for the mouse PAS A domain 
(residues 110 to 267) at a resolution of 2.55 Å (PDB ID: 4M4X) (See Figure 3). This 
X-ray diffraction-based PAS A homodimer structure was obtained from recombi-
nant E. coli expression. It contained a five β-sheet and elements order B-A-I-H-G, 
with four α-helices (Cα, Dα, Eα, and Fα) adjoining one side of the β-sheet. The 
interactions between the two PAS A monomers involved two distinctive areas 
within the A′ α-helices, revealing a strong interaction between Phe115, Leu116, 
and Ala119 from the A′ α-helix in one monomer with Val124, Phe260, and Ile262 
from the β-sheet in the other monomer as shown in Figure 3. The protein structure 
revealed an undruggable pocket due to hydrophobic residues, and other residues 
such as Gln112 and Ile262 are essential in the interface for AHR dimerization, either 
homodimer or heterodimer with ARNT [37, 38]
Two more additional AhR structures were revealed in 2017 (see Figure 4). 
The two structures comprise multiple AhR domains and show a clear interaction 
between AhR and its dimerization partner, ARNT, as well as its interaction with two 
DNA strands. The two structures (PDB IDs: 5V0L and 5NJ8) [39, 40] were resolved 
at a resolution of 4.0 and 3.35 Å, respectively and revealed the complex formation 
among the bHLH and PAS A domains from human AhR and their interactions with 
ARNT and DNA. However, due to the observed high flexibility of the AhR PAS B 
domain and the transactive domain (C- terminal), none of these two subdomains 
were included in this architecture. However, both structures clearly explain the 
protein–protein interactions (PPI) and show clear interface regions for these 
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interactions between the individual domains within AhR as well as their interac-
tions with ARNET and DNA.
As shown in Figure 4, the first PPI interface is between the AhR-ARNT het-
erodimer with the two DNA strands. This interaction is mediated by DRE Ser36, 
His39, and Arg40 from the AhR bHLH domain and His79, Asp83, Arg86, and 
Arg87 from ARNT, as well as thymine and guanine from the DNA. The second 
PPI interface is between AhR and ARNT through different regions within the 
two proteins. These regions involve many hydrophobic interactions from both 
proteins and comprise residues Leu47, Leu50, Leu53, Val74, and Leu70 from the 
AhR bHLH domain and residues Ile109, Leu112, Val136, and Met139 in ARNT. 
The third PPI interface involves interactions between residues from the PAS A 
domain in both AhR and ARNT, mediated by residues Phe117, Leu118, Ala121, 
Leu122, Tyr137, Val126, Phe266, and Ile268 from AhR. The fourth, and final PPI 
interface encompasses the interdomain interactions between the AhR bHLH 
Figure 3. 
The upper figure represents crystal structure of homodimer mouse AhR-PAS a obtained from protein databank 
[37], and the lower figure shows the interactions between the two monomers.
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and AhR PAS A domains, through residues Phe136, Ser151, Ile154, and Leu246 
from the PAS A domain and Phe56, Val60, Leu72, Ala79, and Phe82 from the 
bHLH domain.
4. Applications of computational methods in AhR modeling
The wealth of structural information described above on AhR provides an 
excellent opportunity to apply various computer-based simulations to study the 
dynamicity and structural organization of the various AhR domains. The applica-
tions of such computational tools not only can yield much needed insights on how 
these domains interact together within the AhR machinery, but can also offer 
detailed answers on their interactions with other AhR partners (e.g. ARNT, DNA, 
and chaperone proteins). It can also explain how a small molecule ligand can bind 
to AhR and how this can affect AhR functions, conformational dynamics or its 
interaction with other entities. Computational tools can also suggest novel-binding 
sites either within the AhR structure, or at the interfaces described above to either 
Figure 4. 
Crystal structure of human aryl hydrocarbon receptor in heterodimer with aryl hydrocarbon nuclear 
translocator and recruit on DNA in dioxin element response [40].
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stabilize these interaction (i.e. agonism) or block these interactions (i.e. antago-
nism). Most importantly, computational methods including virtual screening can 
be used as a high throughput-screening tool to identify compounds that can bind to 
these sites to modulate the AhR activity.
4.1 Modeling the PAS B domain
Most of the in silico AhR screening campaigns till now focused on studying 
the PAS B domain. The PAS B domain is also known as the ligand-binding domain 
(LBD), where the ligands (agonists/antagonists) have been shown to bind [41]. 
Given that the available AhR structures (described above) lack this domain, 
computational methods played a key role in studying the interactions of ligands 
with this important region. Towards this goal, homology modeling was used to 
build 3-dimensional structures for this domain to allow the study of ligand bind-
ing to AhR. A homology model approach usually starts with identifying a similar 
template to the target domain (i.e., the PAS B domain in this case). Once a template 
is identified, one uses various computational methods (e.g. sequence alignment, 
threading, and loop modeling) to construct the 3-dimensional structure of the 
target protein [42].
In many AhR studies, the human hypoxia inducible factors (HIF-2α) crystal 
structures served as templates for AhR-PAS B domain because it has the highest 
sequence similarity towards the AhR-PAS B domain. Table 2 provides a list of the 
reported in silico studies that were conducted over the last few years by adopting 
various crystal structures of HIF-2α as starting points to construct PAS B models. 
These studies were focused on understanding the roles played by the different PAS 
B residues in interacting with known AhR modulators and to screen for novel AhR 
ligands. Docking findings from these studies indicated that the binding cavity 
within the AhR-LBD can accommodate ligands with structural maximal dimen-
sions of 14 A ̊ X 12 A ̊ X 5A ̊, and showed that their binding within AhR relies mainly 
on electronic properties [17]. Given this information, various computational meth-
ods including molecular modeling, molecular docking followed by MD simulations, 
and binding free energy calculations were used to provide insights about ligand 
interactions within the PAS B pockets [43].
For example, Bisson and his group established an agonist-optimized model of 
the human AhR-PAS B domain, followed by docking around five thousand chemi-
cal structures, including AhR agonists and antagonists, within the PAS B domain. 
PDB ID Structure method Year of study Reference
3H82 X-ray diffraction 2014 [41]




3F1O, 3H7W, 3H82 X-ray diffraction 2018, 2018 [52, 75]
4XT2 X-ray diffraction 2019 [59]
3F1N, 3F1O, 3F1P, 3H7W, 3H82, 4GHI, 
4GS9, 4XT2, 4ZP4, 4ZQD
X-ray diffraction 2019 [12]
3H82, 3H7W, 4ZQD X-ray diffraction 2020 [61]
Table 2. 
Report studies that used different crystal structures of human hypoxia inducible factors (HIF-2α).
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Docking results were then filtered and the top five systems were subjected to long 
MD simulations (~ 60 ns) to study the conformational and dynamical changes in 
these generated complexes. Findings from Bisson’s work revealed the importance 
of residues 307–329 in the PAS B domain, which were shown to be very flexible, 
acting as an access gate to the ligand-binding pocket. These residues can also adopt 
different conformations upon AhR ligands’ binding and play a primary function in 
controlling the structural changes and accessibility of the ligands to the AhR ligand 
binding pocket [41].
4.2 Interaction of the PAS B domain with different ligands
With the 3-dimensional structure of the PAS B domain in hand, many groups 
focused on studying its binding to different ligands (e.g., TCDD) (shown in 
Figure 5) [44] and investigated this binding reaction for different species. For 
example, TCDD studies on mouse AhR revealed a number of conserved residues 
that regulate the access of TCDD to the binding pocket [45–47]. These residues 
include Thr283, His285, Phe289, Tyr316, Ile319, Cys327, Met334, Phe345, Ala375, 
and Gln377 and have been also shown to control the internal size of the binding 
cavity [48–50]. Similarly, aromatic side chains of Phe 289, Phe 345, and Tyr 316 
were shown to be important in stabilizing TCDD in its best mode of binding via 
non-covalent interaction [48].
Mutations at outer residues (e.g., Arg282, Thr311, Glu339, and Lys350) into ala-
nine did not impact TCDD binding to AhR [51]. In the human AHR-LBD a mutation 
at Ala375 to Val and Leu decreases the binding affinity of TCDD and makes indiru-
bin a less potent endogenous AhR ligand [52, 53]. Additional site-directed mutagen-
esis within AhR-LBD residues has been used to identify key residues promoting for 
ligand selectivity in AhR. These developed models provided a clear basis towards 
understanding the mechanism of ligand-dependent activation of AHR via its PAS 
B domain. In particular, the above mentioned molecular docking and mutagenesis 
Figure 5. 
Chemical structures of AhR ligands in this study obtained from pubchem database.
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analyses helped in identifying and confirming the binding pocket of TCDD and 
other AhR modulators [46, 51, 54, 55].
Examples of these models include those developed by Kim and her team, who 
constructed 3D models from several avian species including, chicken, albatross, and 
cormorant, and studied the sensitivity of dioxin derivatives against multiple AhR 
isoforms. All models were subjected to docking simulations with TCDD followed 
by MD simulations. Kim’s results used the mean square displacement (MSD) of 
the MD trajectories as a stability indicator for the bound ligands. These findings 
revealed Ile324 and Ser380 from chicken AhR1 exhibited the least MSD values com-
pared to all AhR-LBD residues in other avian species. The size of binding pocket 
was also shown to be variable among the different species. Moreover, stabilization 
of TCDD in the binding pocket of chicken AhR relied on the features of Ile324 
and Ser380, which explained why chicken AhR is more sensitive to TCDD binding 
compared to other AhR isoforms [48, 56–58].
Further mutational and functional analysis studies were expanded to include 
additional AhR modulators other than TCCD. For example, the work of Faber and 
her team studied induribin binding to AhR in both mouse and human. This study 
revealed that a mutation in His326Tyr and Ala349Thr in mouse AhR, and Tyr332 
and Thr355 in human AhR can increase the potency of indole compounds, particu-
larly, indirubin. Also, although indirubin and vemurafenib can fit within the same 
binding pocket in AhR, the two compounds showed two different modes of binding 
[52, 59]. For example, flutamide efficiently binds to residues inside the AHR-LBD 
with a high affinity in both mouse and human AHR to activate the AhR pathway 
[60]. It is important to note that, the biological response of AhR is dependant on the 
type of the bound ligand and has been shown to change based on the interaction of 
a given ligand with the residues forming the LBD in the PAS B domain [61, 62].
4.3 Virtual screening and machine learning models applied to AhR
Over the last few decades, virtual screening has been used as a major tool to in 
hit identification campaigns against numerous biological targets [63]. In this regard, 
AhR is no exception and various in silico screening methods have been employed 
to identify new AhR modulators based on the developed 3D models for the PAS B 
domain [13]. These methods can be classified into two major groups; ligand-based 
methods (e.g., quantitative structure–activity relationship (QSAR)) and structure-
based methods (e.g., docking and MD simulations). Ligand-based methods (LB) 
depend on the knowledge of known active/inactive molecules against a given 
target or disease to suggest new active chemical entities. Ligand-based methods are 
typically used when no information about the 3D structure of the target is available. 
They include QSAR, pharmacophore modeling and machine learning algorithms 
methods. QSAR models, for example, correlates the structural, physicochemical 
features, and biological mode of action of known compounds to build a mathemati-
cal model, which can be used to suggest new modifications to these structures for 
better activity or improved biophysical/biochemical properties [64–66].
Pharmacophore modeling maps the ligand-target interactions into a set of steric 
and electronic features structured in a specific 3D arrangement [67]. These pharma-
cophore models can be then used to screen millions of available chemical structural 
libraries for compounds that satisfy these pharmacophore features, which can be 
used for scaffold hopping and fragment-based drug design. On the other hand, 
structure–based methods require the knowledge of target protein crystal structure, 
or its 3D developed homology models. Ligands from a given database can be fitted 
into the active site of the target protein and can be ranked based on the predicted 
binding affinities. In this context, molecular docking and molecular dynamics 
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simulations are among the many valuable tools that can be used to predict the 
most probable mode of binding of a given ligand within the target. Furthermore, 
structure-based pharmacophore models can provide more detailed insights on the 
interaction of ligand with the binding site [66, 68, 69].
As discussed below, several AhR screening studies combined both methods to 
enhance the search for possible AhR candidates [64, 70]. The plethora of accumu-
lated physicochemical, chemical and structural data on AhR modulators augmented 
this hit identification search with great tools to build reliable machine learning 
models, which require large datasets of chemical structures along with their inter-
action kinetics with AhR [71].
An example of AhR in silico screening studies is the one implemented by Xiao 
et al., who constructed 3D structures of the PAS B using the HIF-2α as a template. 
Xiao used his model to study the effects of ~185 polybrominated diphenyl ethers 
(PBDEs), classified as organic pollutants, on AhR activation. This study combined 
molecular docking simulations, two-dimensional quantitative structure–activity 
relationship (2D-QSAR) models, and three-dimensional QSAR (3D-QSAR) models 
to analyze the local ligands’ interactions against a diverse set of PAS B configura-
tions. Their result showed that bromide replacements in at the ortho- or meta-
positions of PBDEs (BDE-49) as shown in the Figure 5 exhibited the largest effect 
on PBDEs’ binding, mainly interacting with residues Met342, Thr290, Met334, 
and Phe289 in the binding site of the AHR-PAS B model in mouse and zebrafish 
[72, 73].
In a similar approach, Rath and his team built two human PAS B domain; a 
wild type and mutant (Val381 Ala, Val381Asn) models. Around 60 natural com-
pounds from Withania somnifera were then docked within these models. Docking 
rustles were then refined using MD simulations for 50 ns. Findings from Rath’s 
study showed that withaferin A, withanolide A, withanolide B, withanolide D 
and withanone were effective as AhR ligands in all three models. In the meantime, 
withanolide A was more stable in the binding site and interacted with various 
residues in each model even after 50 ns of the MD simulations. Withanolide A 
was further validated experimentally in an in vivo zebrafish model to significantly 
reduce CYP1A1 expression. This was done in the presence of a strong AhR activa-
tor, namely benzo[a]pyrene in adult zebrafish brain when administrated together. 
Thus, withanolide A (see Figure 5 and Table 3) neutralized the benzo[a]pyrene 
toxicity in zebrafish brain [74].







Withanolide A + −7.5 [74]
Pinocembrin (5,7-Dihydroxyflavanone, R-form) + −2.9 [55]








+ Not report [75]
Table 3. 
Activation of AhR transcription by chemical compounds that identified by in silico screening of different 
chemical libraries.
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In another screening study, Mahiout, et al. identified IMA-06201 and IMA-
06504 as two novel AhR agonists, with similar modes of binding to that of TCDD. 
Both compounds showed great stability in the central area of the AhR ligand-
binding pocket. Furthermore, these AhR agonists were shown to be more efficient 
and more potent as selective AhR modulators than TCDD. To confirm that, Mahiout 
used CYP1A1 enzyme activity as a biomarker for AhR activation and compared the 
efficacy and potency of IMA-06201 and IMA-06504 (see Figure 5 and Table 3) to 
that of TCDD in the presence and absence of the AhR antagonist, CH-223191, at 
different concentrations in rat hepatoma cell lines. Their results showed that the 
new compounds, IMA-06201 and IMA-06504, were able to induce CYP1A1 activity 
in a similar efficacy to that of TCDD, where CH-223191 was shown to block their 
CYP1A1 induction. Also, in an Ames test to assess the genotoxicity of the new 
identified compounds, IMA-06201 and IMA-06504 did not show mutagenic effects 
at low concentrations [75].
Machine-learning algorithms combined with QSAR have been recently used 
to screen for new AhR ligands. For instance, Matsuzaka used deep learning (DL) 
to construct machine-learning models to predict AhR activators. These models 
showed advantages on enhanced input data based on the 3D chemical structures 
of the compounds into these models, and their performance was better than 
traditional machine learning models [76]. To enhance the screening process of AhR 
ligands, Zhu established a virtual screening protocol from combining ligand-based 
and structure-based screening with supervised machine learning to screen around 
eight thousand from the pesticide databases to identify an agonistic effect on AHR 
activity. Zhu’s results revealed sixteen compounds as AhR activators and these find-
ings were validated in a zebrafish in vivo model to assess their AhR activation and 
exhibited induction in CYP 1a1 levels [77].
Towards improving the prediction accuracy of his model, Yang, et al. used 
machine learning algorithms to construct two-dimensional quantitative structure–
activity relationship (2D-QSAR) models from multiple linear regression (MLR) 
and artificial neural network (ANN) algorithms. He used the pEC50 values of 60 
dioxins derivatives as AhR activators to build. These models predicted the toxicity 
of 162 new dioxin derivatives, showing a good correlation between compounds’ 
chemical structures and their IC50 and EC50 values.
Recently, Goya-Jorge employed various machine learning algorithms to build 
a set of QSAR models. These models adopted the adoboost (AdB), random forest 
(RF), gradient boosting (GB), support vector machine (SVM), and multilayer 
perceptron (MLP) as classifiers to examine around 1900 compounds from synthetic 
and natural sources on their AhR agonism. Around 40 compounds baring the ben-
zothiazole scaffold were classified as AhR agonists. In vitro validation of these hits 
showed that indole derivatives can serve as AhR ligands, including the endogenous 
substances [78, 79]. Table 3 reports some of the top hits emerging from different in 
silico studies.
5. Current challenges in modeling AhR
Identifying novel AhR modulators using in silico approaches require establish-
ing more comprehensive computational models of this target. These models should 
describe the detailed organization of the different AhR domains as well is its 
interaction with other protein/DNA partners. While the available crystal structures 
provide a glimpse of these missing pieces of information, there are still more to 
be done in this regard. For example, all currently available AhR crystal structures 
deposited in the protein data bank are lacking two important AhR domains, namely 
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the PAS B domain and the transactivation domain [40]. The transactivation domain 
is essential in AhR intercellular trafficking.
On the other hand, the PAS B domain interacts with an AhR ligand, which can 
modulate the AhR activity. While homology modeling has helped constructing 
acceptable models for this domain, the similarity of the templates used to build 
the PAS B domain is very low, leaving a lot of doubt about their accuracy. A crystal 
structure of the PAS B domain would be a great leap forward towards understand-
ing the mode of action of AhR modulators and towards identifying better agonists/
antagonists for this important target. Furthermore, there is a gap of knowledge 
on how AhR interact with other protein partners in the inactive state, including 
co-chaperone, AIP, and the protein kinase SRC. This builds an additional challenge 
to identify druggable pockets at their protein–protein interfaces [7, 82]. With the 
apparent advances in obtaining 3D experimental structures of protein (e.g. Cryo-
electron microscopy (cryo-EM)) one expects several of these structural challenges 
can be solved in the near future, opening new gates for the computational science to 
identify new AhR modulators and to help understand its functional, structural and 
biological characterizes more clearly.
6. Executive summary
The AhR is a ligand-activated transcriptional factor. It regulates various 
genes’ expression and plays a pathophysiological function in numerous diseases. 
Crystallography has been employed to resolve three crystal structures containing 
bHLH and PAS A domains from human and mouse origin and to identify four 
protein–protein interfaces. However, all these structures lacked the PAS B domain, 
which plays a fundamental role in ligands’ binding domain to AhR. Computational 
and mutational studies revealed important residues that constitute the binding 
pockets within the PAS B domain. Towards identifying novel AhR modulators, 
several virtual screening and machine learning algorithms were constructed based 
on the available structural and pharmacological properties of known AhR ligands. 
Computational methods are extremely fast and intensely reduce the cost and time 
in screening millions of compounds to find compounds that could interact with the 
AhR. Recent studies employing these methods against AhR have been reviewed and 
discussed in this chapter. We hope the literature presented here can help advance 
the development of novel, selective and potent AhR modulators.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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